News
10-22-2018, 12:00 AM
Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.
More... (https://www.news-medical.net/news/20181022/Phase-III-trial-reports-positive-results-with-HDAC-inhibitor-in-advanced-breast-cancer-patients.aspx)
More... (https://www.news-medical.net/news/20181022/Phase-III-trial-reports-positive-results-with-HDAC-inhibitor-in-advanced-breast-cancer-patients.aspx)